세계의 식물성 의약품 및 식물 유래 의약품 시장 규모는 2025년 387억 달러에서 예측 기간 중 CAGR 8.5%로 추이하며, 2030년말에는 581억 달러에 달할 것으로 전망되고 있습니다.
아시아태평양은 2025년 131억 달러에서 예측 기간 중 CAGR 9.6%로 추이하며, 2030년말에는 208억 달러에 달할 것으로 전망되고 있습니다. 유럽 시장은 2025년 117억 달러에서 예측 기간 중 CAGR 8.3%로 추이하며, 2030년말에는 175억 달러에 달할 것으로 예측됩니다.
세계의 식물성 의약품 및 식물 유래 의약품 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 동향, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
시장 전망
조사 범위
시장 요약
개요
현재 시장 시나리오
부문 분석
신규 기술
결론
제2장 시장 개요
개요
식물 유래 의약품의 역사
고대 이집트의 치료법(기원전 1500년경)
중국 전통의학(고대)
전통 약전에서의 식물 유래 제품
퀴닌 : 기나나무 유래 말라리아 치료의 획기적 성과(17세기)
아스피린 : 버드나무 껍질에 유래하는 의약품(19세기)
식물성 의약품 밸류체인
재배와 채취
일차 처리
규제, 제조, 소비자
거시경제 요인 분석
인구통계학적 요인
지정학적 요인
미국 관세의 영향
Porter's Five Forces 분석
제3장 시장 역학
시장 역학
시장 성장 촉진요인
천연 유래 치료제에 대한 소비자 선호도의 변화
양호한 안전성 및 인용성 개요
추출, 정제, 분석 기술의 진보
고령화와 만성질환의 증가
지원적 규제 구조
시장 성장 억제요인
복잡한 구성과 표준화의 결여
식물성 의약품의 연구개발에 대한 자금부족
시장 기회
식물 대사 산물의 Drug Discovery에 대한 응용
맞춤형 의료 개발을 위한 바이오테크놀러지 통합의 확대
제4장 규제 상황
개요
미국
유럽
기타 국가
제5장 신규 기술과 개발
주요 포인트
싱글 오믹스 어프로치
멀티오믹스 어프로치
발효 기술
파이프라인 분석
주요 포인트
제6장 시장 세분화 분석
세분화 내역
제품 유형별 시장 분석
주요 포인트
식물성 의약품
식물 유래 의약품
용도별 시장 분석
주요 포인트
암
심혈관 질환
중추신경계 질환
감염증
기타
지역적 내역
지역별 시장 분석
북미
유럽
아시아태평양
세계의 기타 지역
제7장 경쟁 정보
주요 포인트
경쟁 분석
대형 제약 기업
식물성 의약품 기업
전략적 구상
제8장 식물성 의약품 및 식물 유래 의약품 시장에서의 지속가능성 : ESG의 관점
ESG 입문
식물성 의약품 및 식물 유래 의약품 업계에서 지속가능성의 동향과 구상
결론
제9장 부록
조사 방법
전시
두자어
기업 개요
ANI PHARMACEUTICALS INC.
BAYER AG
BRISTOL-MYERS SQUIBB CO.
CHIESI FARMACEUTICI S.P.A.
FRESENIUS KABI AG
GSK PLC
JAGUAR HEALTH
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
MALLINCKRODT
MEDIWOUND
NOVARTIS AG
PFIZER INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
신규 스타트업 기업/시장 디스럽터
KSA
영문 목차
영문목차
The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.
The Asia-Pacific market for botanical and plant-derived drugs is expected to grow from $13.1 billion in 2025 and is projected to reach $20.8 billion by the end of 2030, at a CAGR of 9.6% during the forecast period of 2025 to 2030.
The European market for botanical and plant-derived drugs is expected to grow from $11.7 billion in 2025 and is projected to reach $17.5 billion by the end of 2030, at a CAGR of 8.3% during the forecast period of 2025 to 2030.
Report Scope
The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.
This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
Report Includes
47 data tables and 47 additional tables
An overview of the global market for botanical and plant-derived drugs
In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
Analysis of drivers, challenges and opportunities affecting market growth
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion
Chapter 2 Market Overview
Overview
History of Plant-Derived Medicines
Ancient Egyptian Healing Practices (Circa 1500 BCE)
Chinese Herbal Medicine (Ancient times)
Plant-Derived Products in the Traditional Pharmacopeias
Quinine: A Malaria Breakthrough from Cinchona (17th Century)
Aspirin: A Gift from the Willow Tree (19th Century)
Botanical Drugs Value Chain
Cultivation and Collection
Primary Processing
Regulatory, Manufacturing and Consumers
Macroeconomic Factors Analysis
Demographic Factors
Geopolitical Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential of New Entrants: Moderate to High
Bargaining Power of Suppliers: Moderate to High
Bargaining Power of Buyers: Moderate
Threat of Substitute Products or Services: Moderate
Level of Competitiveness: High
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Shift in Consumer Preference for Natural-Origin Therapeutics
Favorable Safety and Tolerability Profile
Advances in Extraction, Purification, and Analytical Technologies
Aging Population and the Growing Prevalence of Chronic Diseases
Supportive Regulatory Frameworks
Market Restraints
Complex Composition and Lack of Standardization
Lack of Funding for Botanical Drugs R&D
Market Opportunities
Application of Plant Metabolites for Drug Discovery
Growing Biotechnological Integration for Personalized Medicine Development
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Other Countries
Chapter 5 Emerging Technologiesand Developments
Key Takeaways
Single-Omics Approaches
Multi-Omics Approaches
Fermentation Technology
Pipeline Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Product Type
Key Takeaways
Botanical Drugs
Plant-Derived Drugs
Market Analysis by Application
Key Takeaways
Cancer
Cardiovascular Diseases
Central Nervous System Disorders
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Analysis
Large Pharmaceutical Companies
Botanical Drug Companies
Strategic Initiatives
Chapter 8 Sustainability in the Botanical and Plant-Derived Drugs Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
